Malaria treatments
To diagnose malaria, the doctor will likely review your medical history and recent travel, conduct a physical exam, and order blood tests. Treatment of Malaria depends on the species of Malaria as well as on the severity of the disease. Blood tests can indicate; The presence of the parasite in the blood, to confirm that you have malaria; The type of malaria parasite is causing your symptoms; If your infection is caused by a parasite resistant to certain drugs or; Whether the disease is causing any serious complications.
People traveling to areas where malaria is common typically take protective drugs before, during and after their trip. Treatment includes antimalarial drugs. The first-line treatment recommended by WHO for most Malaria cases is Artemisinin-based Combination Therapy (ACT). These medicines are available to treat and in some cases prevent Malaria.
The types of drugs and the length of treatment will vary, depending on: the type of malaria parasite one has, the severity of one’s symptoms, age, or whether the patient is pregnant.
The history of vaccines report that, due to the complicated life cycle of Plasmodium, there has been a challenge in trying to develop a malaria vaccine. Researchers must determine which life stage of the parasite to target, or whether the vaccine needs to combine elements that target more than one life stage. In October 2021, WHO finally recommended Mosquirix (RTS,S/AS01) (RTS,S) vaccine for children in Sub-Saharan Africa and in other regions with moderate to high P. falciparum malaria transmission.
This is the only approved vaccine the UN agency had approved as of 2021. Mosquirix requires four injections in children from 5 months of age for the reduction of malaria disease and burden. The malaria vaccine Mosquirix, produced by pharmaceutical company GlaxoSmithKline, was rolled out in 2019.
Though Malaria is a treatable disease, prevention and protection remain to be the best options to fight Malaria. Vector control is the best way to stop spread of Malaria. NOMAK introduces MOZZI in Africa. This product is chemically constructed to provide vector control solutions against mosquitoes. It is used to treat fabrics, walls and most of the places we use that mosquitoes hide. Once treated, they become repellant to disease carrying insects like mosquitoes.
If you don’t kill mosquitoes, they don’t mutate. The MOZZI mosquito repellant is user friendly to both human beings and the environment.
These products don’t have side effects, they are not poisonous and can be used with other products. The mosquito repellant is multi functional in that it is anti-mosquito and anti-bacterial. It’s efficiently long lasting thus keeps on repelling mosquitoes.
NOMAK is on the front line to fight against the spread of Malaria and is certain that MOZZI is a positive solution to Africa when it comes to this fight.